EUVIMEDEUVIMED entdecken
Crossref

2828-LB: BACH01, a Nanoengineered Platform Enabling Oral Semaglutide with Preclinical Evaluation

JIN JUNG

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2828-lb ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von JIN JUNG.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: The efficacy of GLP-1RAs is well established, and development has shifted toward improving safety and patient convenience. Oral formulations could enhance treatment adherence but remain limited by poor gastrointestinal stability and low bioavailability of peptide drugs, even with SNAC-based technologies. To overcome these limitations, we developed the NanoLink platform, an innovative mesoporous nanoparticle-based DDS designed to enhance bioavailability, and evaluated the preclinical feasibility of this nano-engineered oral GLP-1RA formulation.

Methods

Approximately 600 mesoporous silica nanoparticles (MSNs) across five structural types were synthesized based on a target candidate profile and characterized by TEM and DLS. About 250 candidates were further screened for surface charge and pore size, followed by encapsulation of semaglutide, tirzepatide, and survodutide, release kinetics, cellular uptake, and pharmacokinetic evaluation, leading to the selection of two candidates with the highest oral bioavailability.

Results

The two lead formulations showed MSN sizes of 70-200 nm with tunable surface charge, high drug loading (>90%), release (~60%/24 h), strong cellular uptake (>80%), and stable physicochemical properties under scalable manufacturing conditions. PD studies demonstrated significant glucose lowering and body weight reduction. PK analysis showed significantly improved oral bioavailability compared to control with increased Cmax and AUC in small and mid-size animals, highlighting translational and manufacturing potential. In parallel, preclinical studies, including DRF and ADME, are ongoing.

Conclusion

These findings demonstrate that the nano-engineered BACH01 platform enables scalable oral delivery of peptide therapeutics, including GLP-1RAs. The lead candidates have progressed into preclinical development, supporting potential clinical translation of next-generation oral incretin therapies for diabetes, obesity, and related metabolic diseases. Disclosure J. Jung: None.

Zitieren

APA

JUNG, J. (2026). 2828-LB: BACH01, a Nanoengineered Platform Enabling Oral Semaglutide with Preclinical Evaluation. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2828-lb

Vancouver

JUNG J. 2828-LB: BACH01, a Nanoengineered Platform Enabling Oral Semaglutide with Preclinical Evaluation. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2828-lb

BibTeX
@article{JUNG2026,
  author = {JUNG, JIN},
  title = {2828-LB: BACH01, a Nanoengineered Platform Enabling Oral Semaglutide with Preclinical Evaluation},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2828-lb}
}
Kostenlos starten →